Evidence map›Paper›PMID 42212163›Full record

ArticleFrontiers in immunology2026

Assessing the translational relevance of specific molecular pathways in spontaneous lupus mouse models.

María Rivas-Torrubia, María Morell, Zuzanna Makowska, Jorge Kageyama, Anne Bosshard, Julius Lindblom, Maria Orietta Borghi, Eleonore Bettacchioli, PRECISESADS flow cytometry consortium, PRECISESADS clinical consortium and 8 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

María Rivas-Torrubia *Genyo. Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research, Granada, Spain.
María Morell *Genyo. Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research, Granada, Spain.
Zuzanna Makowska *Bayer Pharma AG, Berlin, Berlin, Germany.
Jorge KageyamaBayer Pharma AG, Berlin, Berlin, Germany.
Anne BosshardBayer Pharma AG, Berlin, Berlin, Germany.
Julius LindblomDivision of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
Maria Orietta BorghiImmunorheumatology Research Laboratory, IRCCS Istituto Auxologico Italiano, Milan, Italy.
Eleonore BettacchioliLymphocytes B, Autoimmunité et Immunothérapies (LBAI), UMR 1227, Institut National de la Santé et de la Recherche Médicale (INSERM), University of Western Brittany, Brest, France.
PRECISESADS flow cytometry consortium
PRECISESADS clinical consortium
Ioannis ParodisDivision of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
Lorenzo BerettaReferral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.
Concepción MarañónGenyo. Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research, Granada, Spain.
Jacques-Olivier PersLymphocytes B, Autoimmunité et Immunothérapies (LBAI), UMR 1227, Institut National de la Santé et de la Recherche Médicale (INSERM), University of Western Brittany, Brest, France.
Ralf LescheBayer Pharma AG, Berlin, Berlin, Germany.
Fiona McDonaldBayer Pharma AG, Berlin, Berlin, Germany.
Marta E Alarcón-RiquelmeGenyo. Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research, Granada, Spain.
Guillermo BarturenGenyo. Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research, Granada, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by loss of self-tolerance, causing inflammation and tissue damage in multiple organs. Although animal models have advanced our understanding of SLE's molecular basis, recent regulatory changes and longstanding concerns regarding reproducibility and translatability have renewed the need to critically evaluate how these models mirror human disease. Understanding pathway-level similarities and differences between mouse models and human disease is essential, given the marked clinical and molecular heterogeneity of SLE. Methods: Four spontaneous SLE mouse models were studied: MRL Results: The study identified specific molecular pathways driving the phenotype in each mouse model and established a framework describing the dynamics of these phenotype-associated molecular signatures, thereby facilitating the selection of time points of interest for future mouse-oriented experimental designs. In addition, by comparing these pathways with those observed in human SLE, we identified the most similar ones and their relationship with disease activity, providing crucial insight into their translational relevance. Importantly, disease severity across models was linked to both the extent and timing of molecular dysregulations. As expected, MRL Conclusions: These findings provide a valuable framework for future SLE research and reinforce the utility of mouse models for studying specific molecular pathways related to human SLE pathogenesis and heterogeneity. The integration of longitudinal mouse and human molecular information highlights the models that best recapitulate key aspects of human disease, offering guidance for the study of specific immunopathological mechanisms or therapeutic targets.

Indexed as

Lupus Erythematosus, SystemicAnimalsAutoantibodiesCytokinesDisease Models, AnimalFemaleGene Expression ProfilingHumansMiceMice, Inbred MRL lprMice, Inbred NZBSignal TransductionSpleenTranscriptomeTranslational Research, BiomedicalAutoantibodiesCytokinesautoantibodiescytokinesflow cytometrymolecular integrationmouse modelssystemic lupus erythematosus

Identifiers

PMID42212163
PMCPMC13212498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.